| Quantity | 1Set | 300U | 100mg, 5mg, 50mg, 10mg, 25mg | 10mg, 5mg, 50mg, 1mg, 25mg | 100g, 500g, 25g |
| Description | IGSF9 Human Pre-designed siRNA Set A contains three designed siRNAs for IGSF9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components IGSF9 siRNA-1: 5 nmol (HPLC) IGSF9 siRNA-2: 5 nmol (HPLC) IGSF9 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:IGSF9 Human Pre-designed siRNA Set A contains three designed siRNAs for IGSF9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components IGSF9 siRNA-1: 5 nmol (HPLC) IGSF9 siRNA-2: 5 nmol (HPLC) IGSF9 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Unit Definition One unit will cause a change in A600 of 0.330 per minute at pH 5.7 at 37°C in a 2.0 ml reaction mixture (45 minute assay) | IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compoundIRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC 50 of 0.82 µM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC 50 =3.12 µM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines.In VitroIRE1α kinase-IN-2 (compound 3) inhibits XBP1 mRNA splicing, even during ER stress. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid... Read More | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | Inquire |